Diabetes-drug developer raises $200M in private funding round

04/2/2014 | American City Business Journals

Intarcia Therapeutics said it has secured $200 million in a private equity funding round led by RA Capital. The Boston-based drugmaker is developing a once-a-year diabetes treatment called ITCA 650, a reformulation of AstraZeneca's glucagonlike peptide-1 agonist exenatide. The drug is in a late-stage trial.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ